I.M. Markusse

491 total citations
24 papers, 354 citations indexed

About

I.M. Markusse is a scholar working on Rheumatology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, I.M. Markusse has authored 24 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Rheumatology, 9 papers in Pathology and Forensic Medicine and 7 papers in Genetics. Recurrent topics in I.M. Markusse's work include Rheumatoid Arthritis Research and Therapies (22 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). I.M. Markusse is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (22 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). I.M. Markusse collaborates with scholars based in Netherlands, United States and Italy. I.M. Markusse's co-authors include T. Huizinga, Cornelia F Allaart, Willem F. Lems, P. J. S. M. Kerstens, Linda Dirven, H. K. Ronday, J.H.L.M. van Groenendael, Andreas Gerards, P. B. J. de Sonnaville and Lucia J.M. Kroft and has published in prestigious journals such as Annals of Internal Medicine, Annals of the Rheumatic Diseases and Lara D. Veeken.

In The Last Decade

I.M. Markusse

23 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I.M. Markusse Netherlands 9 276 115 88 62 60 24 354
D. Ruiz-Montesinos Spain 7 247 0.9× 35 0.3× 77 0.9× 40 0.6× 74 1.2× 21 317
Fedra Irazoque-Palazuelos Mexico 10 464 1.7× 66 0.6× 180 2.0× 115 1.9× 155 2.6× 24 539
Michael Batley United Kingdom 4 317 1.1× 60 0.5× 71 0.8× 35 0.6× 52 0.9× 6 423
Emily Sutton United Kingdom 7 194 0.7× 89 0.8× 37 0.4× 14 0.2× 95 1.6× 15 298
Nicola Tyson United Kingdom 5 131 0.5× 183 1.6× 65 0.7× 160 2.6× 136 2.3× 6 376
T. Tison Italy 8 65 0.2× 79 0.7× 109 1.2× 133 2.1× 98 1.6× 19 281
P. B. J. de Sonnaville Netherlands 14 525 1.9× 90 0.8× 195 2.2× 123 2.0× 88 1.5× 18 599
Adriana Sánchez-Ortíz Mexico 8 199 0.7× 51 0.4× 58 0.7× 28 0.5× 72 1.2× 12 290
D. Aletaha Austria 4 465 1.7× 34 0.3× 208 2.4× 44 0.7× 211 3.5× 4 524
Matthias Schneider Germany 6 402 1.5× 25 0.2× 96 1.1× 36 0.6× 164 2.7× 11 462

Countries citing papers authored by I.M. Markusse

Since Specialization
Citations

This map shows the geographic impact of I.M. Markusse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I.M. Markusse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I.M. Markusse more than expected).

Fields of papers citing papers by I.M. Markusse

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I.M. Markusse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I.M. Markusse. The network helps show where I.M. Markusse may publish in the future.

Co-authorship network of co-authors of I.M. Markusse

This figure shows the co-authorship network connecting the top 25 collaborators of I.M. Markusse. A scholar is included among the top collaborators of I.M. Markusse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I.M. Markusse. I.M. Markusse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Markusse, I.M., Sytske Anne Bergstra, Robbert J Goekoop, et al.. (2018). Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis. RMD Open. 4(1). e000649–e000649. 10 indexed citations
3.
Markusse, I.M., S. P. van Mens, & Peter J. de Vries. (2018). An unusual causative pathogen of sepsis after a cat bite: Anaerobiospirillum succiniciproducens.. PubMed. 76(2). 87–89. 3 indexed citations
4.
Allaart, Cornelia F, I.M. Markusse, & Willem F. Lems. (2017). What have we learned from BeSt?. Clinical Immunology. 186. 74–78. 3 indexed citations
5.
Markusse, I.M., Linda Dirven, Yvonne P M Goekoop-Ruiterman, et al.. (2016). Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment. Annals of Internal Medicine. 164(8). 2 indexed citations
6.
Markusse, I.M., Y P M Goekoop-Ruiterman, M. van Oosterhout, et al.. (2016). Assessment of Two Different DAS Treatment Targets in Early Active Rheumatoid Arthritis Patients. Data Archiving and Networked Services (DANS). 68. 1 indexed citations
7.
Markusse, I.M., Y P M Goekoop-Ruiterman, Gerda M. Steup‐Beekman, et al.. (2016). Rheumatologists’ adherence to a disease activity score steered treatment protocol in early arthritis patients is less if the target is remission. Clinical Rheumatology. 36(2). 317–326. 9 indexed citations
8.
Markusse, I.M., Robert Landewé, Ron Wolterbeek, et al.. (2016). Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis. Lara D. Veeken. 55(7). 1295–1300. 6 indexed citations
9.
Markusse, I.M., Jaap Bakker, H. Schippers, et al.. (2016). Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies. Lara D. Veeken. 56(7). kew402–kew402. 53 indexed citations
10.
Matthijssen, X., I.M. Markusse, T. Stijnen, et al.. (2016). Age affects joint space narrowing in patients with early active rheumatoid arthritis. RMD Open. 2(2). e000338–e000338. 2 indexed citations
11.
Markusse, I.M., Linda Dirven, Yvonne P M Goekoop-Ruiterman, et al.. (2016). Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment. Annals of Internal Medicine. 164(8). 523–531. 87 indexed citations
12.
Markusse, I.M., Linda Dirven, Andreas Gerards, et al.. (2015). Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study. Arthritis Research & Therapy. 17(1). 232–232. 85 indexed citations
13.
Markusse, I.M., Linda Dirven, K. H. Han, et al.. (2015). Evaluating Adherence to a Treat‐to‐Target Protocol in Recent‐Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation. Arthritis Care & Research. 68(4). 446–453. 20 indexed citations
14.
Bergstra, Sytske Anne, I.M. Markusse, H. K. Ronday, et al.. (2015). Erosions in the foot at baseline are predictive of orthopaedic shoe use after 10 years of treat to target therapy in patients with recent onset rheumatoid arthritis. Clinical Rheumatology. 35(8). 2101–2107. 2 indexed citations
15.
Markusse, I.M., Linda Dirven, Karel Ronday, et al.. (2015). OP0048 Survival in Early Rheumatoid Arthritis Patients After 10 Years of Targeted Treatment. Annals of the Rheumatic Diseases. 74. 84–85. 1 indexed citations
16.
Markusse, I.M., Linda Dirven, K. H. Han, et al.. (2015). Evaluating adherence to a treat-to-target protocol in recent-onset rheumatoid arthritis: Reasons for compliance and hesitation: Evaluating adherence to targeted treatment. 1 indexed citations
17.
Markusse, I.M., Linda Dirven, K. H. Han, et al.. (2014). Mortality in a Large Cohort of Patients with Early Rheumatoid Arthritis That Were Treated-to-Target for 10 Years.. Data Archiving and Networked Services (DANS). 66. 6 indexed citations
18.
Markusse, I.M., Linda Dirven, Marianne van den Broek, et al.. (2014). A Multibiomarker Disease Activity Score for Rheumatoid Arthritis Predicts Radiographic Joint Damage in the BeSt Study. The Journal of Rheumatology. 41(11). 2114–2119. 32 indexed citations
19.
Markusse, I.M., Jeska K de Vries‐Bouwstra, Anne A. Schouffoer, et al.. (2014). Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis. Arthritis Research & Therapy. 16(5). 430–430. 4 indexed citations
20.
Markusse, I.M., Linda Dirven, Maries van den Broek, et al.. (2014). THU0257 Acpa-Negative RA Patients Benefit from Initial Combination Therapy with Early Clinical Improvement - A Sub-Analysis of the Best Study. Annals of the Rheumatic Diseases. 73. 271–272. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Ruiz-Montesinos Breakdown of academic impact, for papers by Fedra Irazoque-Palazuelos Breakdown of academic impact, for papers by Michael Batley Breakdown of academic impact, for papers by Emily Sutton Breakdown of academic impact, for papers by Nicola Tyson Breakdown of academic impact, for papers by T. Tison Breakdown of academic impact, for papers by P. B. J. de Sonnaville Breakdown of academic impact, for papers by Adriana Sánchez-Ortíz Breakdown of academic impact, for papers by D. Aletaha Breakdown of academic impact, for papers by Matthias Schneider
Rankless by CCL
2026